How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Leucht, S, Arbter, D, Engel, R R, Kissling, W, Davis, J M·2009·Molecular Psychiatry

DOI 10.1038/sj.mp.4002136

Cited by (489)

Items 101–200 of 489

Impaired integration of disambiguating evidence in delusional schizophrenia patients
Nicole Sanford, Ruth Veckenstedt, Steffen Moritz, Ryan P. Balzan, Todd Stephen Woodward · 2014 · Psychological Medicine
Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
Jan Volavka, Leslie Citrome · 2009 · Expert Opinion on Pharmacotherapy
The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample
Nicola J. Morant, Kiran Azam, Sonia Johnson, Joanna Moncrieff · 2017 · Journal of Mental Health
Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice
Su Mi Park, Meng Chen, Claire M. Schmerberg, Russell S. Dulman, Ramona M. Rodriguiz, Marc G. Caron, Jian Jun Jin, William C. Wetsel · 2015 · Neuropsychopharmacology
Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
Emanuela Martinuzzi, Susana Barbosa, Douglas Daoudlarian, Wafa Bel Haj Ali, Cyprien Gilet, Lionel Fillatre, Olfa Khalfallah, Réjane Troudet, Stéphane Jamain, Guillaume B. Fond et al. · 2019 · Translational Psychiatry
Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data
Mark Savill, Ciara Banks, Husnara Khanom, Stefan Priebe · 2014 · Psychological Medicine
Systematic evaluation of commercial pharmacogenetic testing in psychiatry
Chad Bousman, Philip Jaksa, Christos Pantelis · 2017 · Pharmacogenetics and Genomics
Factors modifying drug and placebo responses in randomized trials for bipolar mania
Ayşegül Yıldız, Eduard Vieta, Mauricio F. Tohen, Ross J. Baldessarini · 2011 · The International Journal of Neuropsychopharmacology
Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis
Daniela Polese, Michele Fornaro, Mario Palermo, Vincenzo De Luca, Andrea de Bartolomeis · 2019 · Frontiers in Psychiatry
Pharmacological treatment of negative symptoms in schizophrenia
Hans‐Jürgen Möller, Pál Czobor · 2015 · European Archives of Psychiatry and Clinical Neuroscience
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Willie R. Earley, Hua Guo, David Gordon Daniel, Henry A. Nasrallah, Suresh Durgam, Yan Zhong, Mehul Patel, Ágota Barabássy, B. Szatmári, György Németh · 2018 · Schizophrenia Research
Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort
Ophélia Godin, Marion Leboyer, Alexandru Gaman, Bruno Aouizerate, Fabrice Sébastien Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chéreau, Jean‐Michel Dorey, Caroline Dubertret et al. · 2015 · Schizophrenia Research
Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions.
Rief, W., Barsky, A.J., Bingel, U., Doering, B.K., Schwarting, R., Wöhr, M., Schweiger, U. · 2016 · Neuroscience & Biobehavioral Reviews
Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.
Richard S.E. Keefe, HELENA CHMURA KRAEMER, Robert S. Epstein, Ellen Frank, Ginger Haynes, THOMAS P. LAUGHREN, James P. McNulty, Shelby D. Reed, Juan Sanchez, Andrew C. Leon · 2013 · Europe PMC (PubMed Central)
No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis
Konstantinos Ν. Fountoulakis, Areti Angeliki Veroniki, Melina Siamouli, Hans‐Jürgen Möller · 2013 · Annals of General Psychiatry
Effective elements of cognitive behaviour therapy for psychosis: results of a novel type of subgroup analysis based on principal stratification
Graham Dunn, David G. Fowler, Rebecca Rollinson, Daniel H. Freeman, Elizabeth Kuipers, Benjamin Smith, Craig Steel, Juliana Onwumere, Suzanne Jolley, Philippa Anne Garety et al. · 2011 · Psychological Medicine
How to read and understand and use systematic reviews and meta‐analyses
Stefan Leucht, Werner Kissling, John M. Davis · 2009 · Acta Psychiatrica Scandinavica
Signal Detection and Placebo Response in Schizophrenia: Parallels with Depression
Craig H. Mallinckrodt, Lu Zhang, William R. Prucka, Brian A. Millen · 2025 · Psychopharmacology Bulletin
Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. a systematic review
Bowtell, Meghan, Ratheesh, Aswin, McGorry, Patrick, Killackey, Eoin, O'Donoghue, Brian · 2018 · Schizophrenia Research
Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis
Albert KK Chung, Siew-eng Chua · 2010 · Journal of Psychopharmacology
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
Robert J. Howard, Elizabeth Cort, Rosie Bradley, Emma Harper, Linda J. Kelly, Peter Bentham, Craig William Ritchie, Suzanne Reeves, Waleed Fawzi, Gill Livingston et al. · 2018 · The Lancet Psychiatry
A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia
Leslie Citrome · 2011 · Expert Opinion on Pharmacotherapy
Living with antipsychotic medication side‐effects: The experience of A ustralian mental health consumers
Paul Morrison, Tom Meehan, Norman Jay Stomski · 2014 · International Journal of Mental Health Nursing
Recent advances in understanding schizophrenia
Chiara Simone Haller, Jaya L. Padmanabhan, Paulo L. Lizano, John Blake Torous, Matcheri S. Keshavan · 2014 · F1000Prime Reports
Metacognitive therapy in treatment-resistant psychosis: a multiple-baseline study.
Hutton, Paul, Morrison, Anthony P., Wardle, Melissa, Wells, Adrian · 2014 · Behavioural and Cognitive Psychotherapy
Antipsychotics and Amotivation
Gagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias, Paul J. Fletcher, Ofer Agid, Gary J. Remington · 2015 · Neuropsychopharmacology
Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis
Meghan Bowtell, Scott Eaton, Kristen Thien, Melissa Bardell-Williams, Linglee Downey, Aswin Ratheesh, Eoin J. Killackey, Patrick D. McGorry, Brian N. O'Donoghue · 2017 · Schizophrenia Research
The Pharmacologic Treatment of Schizophrenia—2021
DONALD C. GOFF · 2020 · JAMA
Combining aerobic exercise and repetitive transcranial magnetic stimulation to improve brain function in health and disease
Joshua J. Hendrikse, Aaron A. Kandola, James P. Coxon, Nigel C. Rogasch, Murat Yücel · 2017 · Neuroscience & Biobehavioral Reviews
Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
Michele Fabrazzo, Salvatore Cipolla, Alessio Camerlengo, Francesco Perris, Francesco Catapano · 2022 · Journal of Clinical Medicine
Converging Evidence for the Association of Functional Genetic Variation in the Serotonin Receptor 2a Gene With Prefrontal Function and Olanzapine Treatment
Giuseppe Blasi, Caterina De Virgilio, Apostolos Papazacharias, Paolo Taurisano, Barbara Gelao, Leonardo Fazio, Gianluca Ursini, Lorenzo Sinibaldi, Ileana Andriola, Rita Masellis et al. · 2013 · JAMA Psychiatry
Six-Month Follow-Up of Recovery-Oriented Cognitive Therapy for Low-Functioning Individuals With Schizophrenia
Paul M. Grant, Keith Bredemeier, Aaron Tim Beck · 2017 · Psychiatric Services
A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial
THE GET UP GROUP, Mirella Ruggeri, Chiara Bonetto, Antonio Lasalvia, Giovanni de Girolamo, Angelo Fioritti, Paola Rucci, Paolo Santonastaso, Giovanni Neri, Francesca Pileggi et al. · 2012 · Trials
Frontale Hirnvolumenminderung durch Antipsychotika?
Volkmar Aderhold, Stefan Weinmann, Claudia Hägele, Andreas Heinz · 2014 · Der Nervenarzt
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Vladimir M. Pogorelov, Ramona M. Rodriguiz, Jianjun Cheng, Mei Huang, Claire M. Schmerberg, Herbert Y. Meltzer, Bryan L. Roth, Alan P. Kozikowski, William C. Wetsel · 2017 · Neuropsychopharmacology
Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?
Steffen Moritz, Christina Andreou, Stefan Klingberg, Teresa Thoering, Maarten J.V. Peters · 2013 · Neuropharmacology
Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis
Gabrielle Le Geyt, Yvonne F. Awenat, Sara Tai, Gillian Haddock · 2016 · Qualitative Health Research
Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling
Giuseppe Carrà, Cristina Crocamo, Matthias C. Angermeyer, Traolach Sean Brugha, Mondher Toumi, Paul Bebbington · 2018 · Schizophrenia Research
Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis)
Tianhong Zhang, Lihua Xu, XiaoChen Tang, YanYan Wei, Qiang Hu, YeGang Hu, HuiRu Cui, Yingying Tang, Li Hui, Chunbo Li et al. · 2020 · Australian & New Zealand Journal of Psychiatry
Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment
Justin Faden, Leslie Citrome · 2018 · Expert Opinion on Pharmacotherapy
Profile of minocycline and its potential in the treatment of schizophrenia
Lulu Zhang, Jingping Zhao · 2014 · Neuropsychiatric Disease and Treatment
Nonadherence to antipsychotics: The role of positive attitudes towards positive symptoms
Steffen Moritz, Alexandra Hünsche, Tania M. Lincoln · 2014 · European Neuropsychopharmacology
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis
Emilio Sacchetti, Chiara Magri, Alessandra Minelli, Paolo Valsecchi, Michele Traversa, Stefano Calza, Antonio Vita, Massimo Gennarelli · 2016 · The Pharmacogenomics Journal
Prediction of early response to overall treatment for schizophrenia: A functional magnetic resonance imaging study
Long‐Biao Cui, Min Cai, Xing‐Rui Wang, Yuanqiang Zhu, Liuxian Wang, Yibin Xi, Huaning Wang, Xia Zhu, Hong J. Yin · 2019 · Brain and Behavior
Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics
Leslie Citrome · 2011 · Postgraduate Medicine
Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study
Naoki Hashimoto, Atsuhito Toyomaki, Minoru Honda, Satoru Miyano, Nobuyuki Nitta, Hiroyuki Sawayama, Yasufumi Sugawara, Keiichi Uemura, Noriko Tsukamoto, Tsukasa Koyama et al. · 2015 · Annals of General Psychiatry
Comparative remission rates of schizophrenic patients using various remission criteria
Romain Beitinger, Jingxia Lin, Werner Kissling, Stefan Leucht · 2008 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis
Stefan Leucht, Andrea Cipriani, Loukia Maria Spineli, Dimitris Mavridis, Deniz Örey, Franziska Richter, Myrto T. Samara, Corrado Barbui, Rolf R. Engel, John Richard Geddes et al. · 2014 · FOCUS The Journal of Lifelong Learning in Psychiatry
Methamphetamine-Induced Sensitization Is Associated with Alterations to the Proteome of the Prefrontal Cortex: Implications for the Maintenance of Psychotic Disorders
Travis A. Wearne, Mehdi Mirzaei, Jane L. Franklin, Ann K. Goodchild, Paul A. Haynes, Jennifer L. Cornish · 2014 · Journal of Proteome Research
Individualized metacognitive therapy for delusions: A randomized controlled rater-blind study
Christina Andreou, Charlotte E. Wittekind, Martina Fieker, Ulrike Heitz, Ruth Veckenstedt, Francesca Bohn, Steffen Moritz · 2016 · Journal of Behavior Therapy and Experimental Psychiatry
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
René S. Kahn, Bernard L. Silverman, Lauren DiPetrillo, Christine E. Graham, Ying Jiang, Jiani C. Yin, Adam Simmons, Vasudev Bhupathi, Bei Yu, Sergey Yagoda et al. · 2021 · Schizophrenia Research
Integrative Circuit Models and Their Implications for the Pathophysiologies and Treatments of the Schizophrenias
Neal R. Swerdlow · 2010 · Current topics in behavioral neurosciences
Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
Morozova Ma, T. A. Lepilkina, G. Rupchev, Бениашвили Аллан Герович, Denis S. Burminskiy, С. С. Потанин, Evgeny V. Bondarenko, Vasily I. Kazey, Yan Lavrovsky, Alexandre V. Ivachtchenko · 2013 · CNS Spectrums
An internet-based intervention for people with psychosis (EviBaS): study protocol for a randomized controlled trial
Nina Rüegg, Steffen Moritz, Thomas Berger, Thies Lüdtke, Stefan Westermann · 2018 · BMC Psychiatry
Can virtual reality reduce reality distortion? Impact of performance feedback on symptom change in schizophrenia patients
Steffen Moritz, Miriam Voigt, Ulf Köther, Lucy Leighton, Besiane Kjahili, Zehra Babur, David Jungclaussen, Ruth Veckenstedt, Karsten Grzella · 2013 · Journal of Behavior Therapy and Experimental Psychiatry
60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response
Stefan Leucht, Anna Chaimani, Claudia Leucht, Maximilian Huhn, Dimitris Mavridis, Bartosz Helfer, Myrto T. Samara, Andrea Cipriani, John Richard Geddes, Georgia Salanti et al. · 2018 · Schizophrenia Research
Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
Stefan Leucht, Anna Chaimani, Dimitris Mavridis, Claudia Leucht, Maximilian Huhn, Bartosz Helfer, Myrto T. Samara, Andrea Cipriani, John Richard Geddes, John M. Davis · 2019 · Neuropsychopharmacology
Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis
Steffen Moritz, Teresa Thoering, Simone Kühn, Bastian Willenborg, Stefan Westermann, Matthias Nagel · 2015 · Frontiers in Psychology
Treating depressive episodes or symptoms in patients with schizophrenia
Geeske van Rooijen, Jentien M. Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan · 2017 · CNS Spectrums
Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders
Venkatesh Pilla Reddy, Magdalena Kozielska, Martin G. Johnson, An Vermeulen, Rik de Greef, Jing Liu, Geny M. M. Groothuis, Meindert Danhof, Johannes H. Proost · 2011 · Clinical Pharmacokinetics
Shared decision making in the recovery of people with schizophrenia: The role of metacognitive capacities in insight and pragmatic language use
Kevin Ka Shing Chan, Winnie W. S. Mak · 2012 · Clinical Psychology Review
A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia
Herbert Y. Meltzer, Jean‐Pierre Lindenmayer, J. Kwentus, Daniel Barrett Share, R. Johnson, Karuna Jayathilake · 2014 · Schizophrenia Research
Calibration and cross-validation of MCCB and CogState in schizophrenia
Jane Lees, Eve Applegate, Richard Emsley, Shôn W. Lewis, Panayiota G. Michalopoulou, Tracy Collier, Cristina Lopez‐Lopez, Shitij Kapur, Gahan Pandina, Richard Drake · 2015 · Psychopharmacology
Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions
Desiree D. Dickerson, David K. Bilkey · 2013 · Frontiers in Behavioral Neuroscience
Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis.
Farnaz Zamani Esfahlani, Hiroki Sayama, Katherine Frost Visser, Gregory P. Strauss · 2017 · PubMed Central
Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations
Hans‐Jürgen Möller, Wolfgang Maier · 2009 · European Archives of Psychiatry and Clinical Neuroscience
A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo
Marianne Klemp, Ingunn Fride Tvete, Tor Skomedal, Jørund Gåsemyr, Bent Natvig, Ivar Aursnes · 2011 · Journal of Clinical Psychopharmacology
Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directions
Nicholas J. K. Breitborde, Aubrey M. Moe, Arielle Ered, Lauren M. Ellman, Emily K. Bell · 2017 · Psychology Research and Behavior Management
The COMMAND trial of cognitive therapy to prevent harmful compliance with command hallucinations: predictors of outcome and mediators of change
Max J. Birchwood, Graham Dunn, Alan Meaden, Nicholas Tarrier, Shôn W. Lewis, Til Wykes, Linda Mary Davies, Maria Michail, EMMANUELLE R. PETERS · 2017 · Psychological Medicine
Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge
Neal R. Swerdlow, Savita G. Bhakta, Gregory A. Light · 2018 · Schizophrenia Research
A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia
Christy Lai Ming Hui, Bertha Sze Ting Lam, Edwin Ho Ming Lee, Sherry Kit Wa Chan, Wing Chung Chang, Yi Nam Suen, Eric Yu Hai Chen · 2019 · International Review of Psychiatry
Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs
Pramod C. Nair, John O. Miners, Ross Allan McKinnon, Christopher J. Langmead, Karen J. Gregory, David Copolov, Sherry Kit Wa Chan, Tarun Joseph Bastiampillai · 2021 · Molecular Psychiatry
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Eiji Kirino · 2017 · Annals of General Psychiatry
Meta-Analyses of the Efficacy of Asenapine for Acute Schizophrenia
Armin Szegedi, Pierre Verweij, Wilbert van Duijnhoven, Mary Mackle, Pilar Cazorla, Hein Fennema · 2012 · The Journal of Clinical Psychiatry
The influence of metacognitive training on delusion severity and metacognitive ability in schizophrenia
Erna Erawati, Budi Anna Keliat, Novy Helena Catharina Daulima, Achir Yani S. Hamid · 2014 · Journal of Psychiatric and Mental Health Nursing
Challenges and opportunities for the development of new antipsychotic drugs
Carlos Forray, R. Buller · 2017 · Biochemical Pharmacology
Possible Role of Glia in Cognitive Impairment in Schizophrenia
Bernhard Mitterauer · 2011 · CNS Neuroscience & Therapeutics
Role of sublingual asenapine in treatment of schizophrenia
Leslie Citrome · 2011 · Neuropsychiatric Disease and Treatment
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology
Hans‐Jürgen Möller, Karl Broich · 2009 · European Archives of Psychiatry and Clinical Neuroscience
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
Steven G. Potkin, Tatsuya Kimura, John J. Guarino · 2015 · Therapeutic Advances in Psychopharmacology
Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication
Joanna Moncrieff, Kiran Azam, Sonia Johnson, Louise Marston, Nicola J. Morant, Katherine Darton, Neil Wood · 2016 · BMC Psychiatry
Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases
Pradeep Paudel, Se Eun Park, Su Hui Seong, Hyun Ah Jung, Jae Sue Choi · 2020 · Journal of Agricultural and Food Chemistry
Antipsychotics in children and adolescents with schizophrenia: A systematic review and meta-analysis
Sandeep Grover, Siddharth Sarkar · 2013 · Indian Journal of Pharmacology
Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study
Panna Sanga, Elena Polverejan, Steven Wang, Kathleen M. Kelly, John Thipphawong · 2016 · Clinical Therapeutics
Cariprazine specificity profile in the treatment of acute schizophrenia
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri · 2017 · International Clinical Psychopharmacology
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic
Leslie Citrome · 2010 · International Journal of Clinical Practice
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis
Benedicto Crespo‐Facorro, Rocío Pérez‐Iglesias, Ignacio Fernandez Mata, Obdulia Martínez‐García, Víctor Ortiz‐García de la Foz, José María Pelayo‐Terán, Elsa M. Valdizán, José Luis Vázquez‐Barquero · 2011 · Psychopharmacology
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program
Stefan Leucht, Jun Zhao · 2014 · Journal of Psychopharmacology
Recent Progress in Pharmacogenomics of Antipsychotic Drug Response
Jianping Zhang, Anil K. Malhotra · 2018 · Current Psychiatry Reports
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
K. Fountoulakis, H. Moeller, S. Kasper, C. Tamminga, S. Yamawaki, R. Kahn, R. Tandon, C. Correll, A. Javed · 2020 · CNS Spectrums
A randomised controlled pilot study of Experience Focused Counselling with voice hearers
Joachim Schnackenberg, Mick P. Fleming, Colin Robert Martin · 2016 · Psychosis
Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial
Nikolai Albert, Lasse Randers, Kelly Allott, Heidi Jensen, Marianne Melau, Carsten Rygaard Hjorthøj, Merete Nordentoft · 2018 · Psychological Medicine
Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success
Miriam Larsen-Barr, Fred W. Seymour, John Read, Kerry L Gibson · 2018 · Psychiatry Research
The efficacy of extended metacognitive training for psychosis: A randomized controlled trial
Ryotaro Ishikawa, Takuma Ishigaki, Takeshi Shimada, Hiroki Tanoue, Naoki Yoshinaga, Naoya Oribe, Takafumi Morimoto, Takeshi Matsumoto, Masahito Hosono · 2019 · Schizophrenia Research
The impact of negative treatment experiences on persistent refusal of antipsychotics
Tania M. Lincoln, Esther Jung, Martin Wiesjahn, Hanna Wendt, Thomas A. Bock, Björn Schlier · 2016 · Comprehensive Psychiatry
Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia
Paul Hutton, Anthony P. Morrison, Alison Ruth Yung, Peter James Taylor, Paul French, Graham Dunn · 2012 · Acta Psychiatrica Scandinavica
Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature
Giulia Maria Giordano, Francesco Brando, Pasquale Pezzella, Maria De Angelis, Armida Mucci, Silvana Galderisi · 2022 · Frontiers in Psychiatry
Motive-oriented therapeutic relationship building for patients diagnosed with schizophrenia
Stefan Westermann, Marialuisa Cavelti, Eva Heibach, Franz Caspar · 2015 · Frontiers in Psychology
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial
Timothy L. Ramsey, Mark D. Brennan · 2014 · Schizophrenia Research
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
Benedicto Crespo‐Facorro, José María Pelayo‐Terán, Jacqueline Mayoral-van Son · 2016 · Neurology and Therapy